EE281 Cost-Effectiveness of Every Two Month Cabotegravir Long-Acting (CAB-LA) for Pre-Exposure Prophylaxis (PREP) Compared with Daily Oral Tenofovir Disoproxil Fumarate (TDF)/ Emtricitabine (FTC) As Prep to Prevent HIV-1 in the UK
Abstract
Authors
P O'Brien K Campbell SJ Anderson L Cornic A Davis M Schroeder